https://www.selleckchem.com/products/Y-27632.html
Most studies excluded people with more severe degrees of renal impairment (eGFR or CrCl of 30 ml/min). For allopurinol, in particular, there was significant variability in the dose of drug used and the efficacy in terms of urate lowering, across all levels of renal impairment. There is a lack of evidence regarding the efficacy and/or safety of currently used ULTs according to different levels of renal function. Future studies should include patients with CKD and should report study outcomes stratified by renal function. There is a l
Like
Comment
Share
